Evidence map›Paper›PMID 41569692›Full record

ArticleJCI insight2026

MYO1C is a urinary extracellular vesicle biomarker and mediator of podocyte injury in diabetic nephropathy.

Zihao Zhao, Qianqian Yan, Sijie Zhou, Fengxun Liu, Yong Liu, Jingjing Ren, Shaokang Pan, Zhenjie Liu, Dongwei Liu, Zhangsuo Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zihao ZhaoDepartment of Radiology, Department of Nephrology, and.
Qianqian YanDepartment of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu, China.
Sijie ZhouNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fengxun LiuNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yong LiuNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jingjing RenNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shaokang PanNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhenjie LiuNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dongwei LiuNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhangsuo LiuNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiayu DuanNephrology Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetic nephropathy (T2DN) is a major complication of type 2 diabetes and a leading cause of chronic kidney disease. This study aimed to explore Myosin IC (MYO1C) as both a candidate biomarker and elucidate its role as a mechanistic mediator of podocyte injury in T2DN. Using urinary extracellular vesicle RNA biomarkers identified from a training and validation cohort of 33 type 2 diabetes and 40 patients with T2DN, we developed a machine learning diagnostic model for T2DN. The model achieved an AUC of 0.877 in validation and performed well in an independent test cohort with an AUC of 0.824. MYO1C was identified as the most influential feature in the final model. Mechanistic investigations in vitro and in vivo revealed that high glucose and high-fat conditions induced podocyte injury, inflammation, and apoptosis, with increased MYO1C expression. MYO1C knockdown in vitro and in vivo reduced podocyte damage and inflammatory responses. MYO1C overexpression enhanced p38, p-CREB, and TNF-α levels, while p38 inhibition mitigated these effects. These findings support MYO1C not only as a potential urinary biomarker for T2DN but also as a key pathogenic driver that promotes podocyte injury via p38 MAPK signaling.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesExtracellular VesiclesMyosin Type IPodocytesAnimalsApoptosisBiomarkersFemaleHumansMaleMiceMiddle Agedp38 Mitogen-Activated Protein KinasesBiomarkersMyosin Type Ip38 Mitogen-Activated Protein KinasesApoptosisBiomarkersInflammationNephrologyUrology

Identifiers

PMID41569692
PMCPMC13041675

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.